Literature DB >> 10224577

Thrombolysis is superior to heparin for non-obstructive mitral mechanical valve thrombosis.

M Lengyel1, G Vegh, L Vandor.   

Abstract

BACKGROUND AND AIM OF THE STUDY: Non-obstructive prosthetic valve thrombosis (PVT) is a unique subset that features clinical presentation without heart failure, and may be asymptomatic. Thrombolysis has been accepted for obstructive PVT, but treatment strategies of non-obstructive PVT are controversial. This study compared the efficacy and safety of thrombolysis and heparin treatment in these patients.
METHODS: Between 1993 and 1998, 20 consecutive patients were found by multiplane transesophageal echocardiography (TEE) to have non-obstructive PVT. TEE was performed for peripheral embolism in two patients, stroke or transient ischemic attack in six, stroke and fever in two, fever in one patient, as a routine postoperative examination in two patients, and for other reasons in seven. Patients were allocated to two groups: group I (n = 8) received streptokinase-mediated fibrinolysis; group II (n = 12) received intravenous heparin by infusion. Treatment was monitored using TEE.
RESULTS: There was no difference between patient groups with regard to sex, age, type of prosthesis and time since operation, though anticoagulant status was more often inadequate in group II. By TEE, valve motion was normal in all patients. In group I, all thrombi were mobile and 5-13 mm in diameter; in group II, all thrombi but three were mobile and 3-18 mm in diameter. In group I, thrombolysis was successful in all patients, without complications, within 6-72 h. In group II, heparin treatment was successful in six patients in 3-32 days. In one patient, seven days' of unsuccessful heparin was followed by two months' successful coumarin therapy. Among five unsuccessful cases, the thrombus size increased in four (three became obstructive in 7-35 days); all four patients were switched to fibrinolysis, which was successful without complications in 12-60 h. The fifth patient developed a stroke after nine days of heparin treatment and was subsequently operated on.
CONCLUSIONS: Non-obstructive PVT may be asymptomatic in one-third of patients. Thrombolysis is an efficient and safe treatment, and may be first-line therapy if there is no contraindication. Heparin treatment was successful in about one-half of our cases in the presence of sessile or small thrombi and inadequate anticoagulant status. In unsuccessful cases, thrombi became obstructive or caused stroke during heparin therapy, the adequate duration of which remains unclear.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10224577

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  5 in total

1.  Recurrent thrombotic obstruction of a mechanical prosthetic valve in tricuspid position. Value of cinefluoroscopy in diagnosis and follow-up of thrombolytic treatment.

Authors:  S Avci; S Yilmaz; O Kus; M F Ucar; D Aras
Journal:  Herz       Date:  2013-08-10       Impact factor: 1.443

2.  Diagnostic value of D-dimer and antithrombin-III levels in predicting prosthetic heart valve thrombosis.

Authors:  Cem Nazli; Ozan Kinay; Bahanttin Tunc; Oktay Ergene; Omer Gedikli; Ali Ayata; Abdullah Dogan; Ahmet Altinbas; Ulku Ergene; Mehmet Ozaydin; Turan Yavuz; Halil Kahraman
Journal:  Tex Heart Inst J       Date:  2003

Review 3.  A global perspective on mechanical prosthetic heart valve thrombosis: Diagnostic and therapeutic challenges.

Authors:  Mustafa Ozan Gürsoy; Macit Kalçık; Mahmut Yesin; Süleyman Karakoyun; Emrah Bayam; Sabahattin Gündüz; Mehmet Özkan
Journal:  Anatol J Cardiol       Date:  2016-12       Impact factor: 1.596

4.  Fibrinolytic Treatment after Transient Ischaemic Attack Caused by Prosthetic Mitral Valve Thrombosis.

Authors:  Cornel Koban; Michael Neuß; Grit Tambor; Frank Hölschermann; Christian Butter
Journal:  Case Rep Cardiol       Date:  2016-05-26

5.  Thrombolytic treatment of prosthetic valve thrombosis: a study using Urokinase.

Authors:  Feng Huang; Yongrong Lan; Zhangbo Cheng; Zili Zhang; Fei Ren
Journal:  J Cardiothorac Surg       Date:  2020-10-01       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.